GlassScriptPhysician profile
Nirali Marvania
NPI 1336646942
$3,779.66
in general payments reported to CMS, 2019-2025
25 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $419 · 2024: $1,878 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,731 · Education: $49.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,730.55 |
| Education | $49.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $451.64 | 2023-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $386.36 | 2024-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $376.38 | 2023-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $214.34 | 2024-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $214.30 | 2024-2025 | |
| Ardelyx, INC. | $195.89 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $188.40 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $188.05 | 2023-2025 | Jynarque |
| Amgen INC. | $178.62 | 2024-2025 | Tavneos, Aranesp, Parsabiv |
| Travere Therapeutics, INC. | $173.15 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $167.55 | 2024-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $165.31 | 2024-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $161.60 | 2024-2025 | |
| Boston Scientific Corporation | $140.03 | 2023 | |
| Opko Pharmaceuticals, LLC | $125.19 | 2024-2025 | Rayaldee |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $70.57 | 2024-2025 | Ultomiris |
| Philips North America LLC | $66.73 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $58.79 | 2025 | |
| Glaxosmithkline, LLC. | $48.38 | 2023-2024 | Jesduvroq |
| Kyowa Kirin, INC. | $47.51 | 2023-2025 | Crysvita |
| Recor Medical INC | $46.34 | 2025 | Paradise Ultrasound Renal Denervation System |
| Calliditas Therapeutics US INC. | $38.65 | 2024-2025 | Tarpeyo |
| Scpharmaceuticals INC. | $30.90 | 2025 | |
| Novo Nordisk INC | $28.27 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.71 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirali Marvania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.